Type IV CRISPR-Cas modules belong to class 1 prokaryotic adaptive immune systems, which are defined by the presence of multisubunit effector complexes. They usually lack the known Cas proteins involved in adaptation and target cleavage, and their function has not been experimentally addressed. To investigate RNA and protein components of this CRISPR-Cas type, we located a complete type IV cas gene locus and an adjacent CRISPR array on a megaplasmid of Aromatoleum aromaticum EbN1, which contains an additional type I-C system on its chromosome. RNA sequencing analyses verified CRISPR RNA (crRNA) production and maturation for both systems. Type IV crRNAs were shown to harbour unusually short 7 nucleotide 5′ -repeat tags and stable 3′ hairpin structures. A unique Cas6 variant (Csf5) was identified that generates crRNAs that are specifically incorporated into type IV CRISPR-ribonucleoprotein (crRNP) complexes. Structures of RNA-bound Csf5 were obtained. Recombinant production and purification of the type IV Cas proteins, together with electron microscopy, revealed that Csf2 acts as a helical backbone for type IV crRNPs that include Csf5, Csf3 and a large subunit (Csf1). Mass spectrometry analyses identified protein-protein and protein-RNA contact sites. These results highlight evolutionary connections between type IV and type I CRISPR-Cas systems and demonstrate that type IV CRISPR-Cas systems employ crRNA-guided effector complexes.
A rchaea and Bacteria have evolved different strategies to cope with foreign nucleic acids. One of these strategies employs CRISPR-Cas systems, described to mediate adaptive immunity by providing defence against viral attacks. The genomic organization of this locus established the term 'clustered regularly interspaced short palindromic repeats' (or CRISPR), and genes that co-localize with this region are termed cas (for CRISPR-associated) genes 1 . The spacer sequences were found to exhibit homology to extrachromosomal sequences (that is, protospacers in viral genomes or plasmid DNA [2] [3] [4] ), and experimental evidence indicated that CRISPR-Cas systems can function as inheritable immune systems 5 . In contrast to other known prokaryotic antiviral measures (for example restriction-modification or abortive infection system), CRISPR-Cas acts specifically on DNA or RNA sequences from previously encountered invaders, which enables an adaptive immune response 6 . The general mechanism of CRISPR-Cas activity is normally divided into three stages-acquisition, expression and interference. During the acquisition stage, a complex, usually containing Cas1 and Cas2 proteins, binds the invading sequence and recognizes a specific 2-5 nucleotide (nt) DNA motif, the protospacer-adjacent motif (PAM) 2, 7, 8 . Subsequently, the protospacer, a PAM-adjacent sequence of defined length, is excised by those Cas proteins 9 . This protospacer is then incorporated as a new spacer sequence into the growing CRISPR array next to a leader sequence 5, 9, 10 . In the expression stage, the CRISPR array is transcribed into a long precursor RNA, the pre-CRISPR RNA (pre-crRNA) 11, 12 . The pre-crRNA molecule is then processed into short mature crRNAs, for example by the Cas protein Cas6 (ref. 13 ). Pre-crRNA processing usually occurs within repeat sequences, which often form hairpin structures due to palindromic sequence elements. Thus, mature crRNAs comprise a spacer sequence flanked by segments of the repeats. Finally, in the interference stage, mature crRNAs are bound by different Cas protein complexes [14] [15] [16] , and base complementarity between the crRNA spacer sequence and the invading DNA or RNA is used for target recognition. Once bound, the associated Cas proteins cleave the targeted sequence, usually leading to full target degradation 17, 18 . A large variety of divergent CRISPR-Cas systems with different repeat arrangements and semi-conserved modules of cas genes have been described. Computational analyses of the CRISPR-Cas loci allowed their classification into two classes and at least six types 19, 20 . In type I systems, interference is carried out by multi-protein complexes, whereas it is achieved by a single Cas protein in type II, V and VI systems 21 . In type III systems, the process is coupled to transcription, where a multi-protein Cas complex targets the nascent mRNA in a PAM-independent manner and degrades close-by DNA 22 . Type I CRISPR-Cas systems are represented by seven subtypes (A-F and U) that contain the conserved DNA helicase/endonuclease Cas3, which is responsible for target degradation 19, 23 . In this type, interference is mediated by a ribonucleoprotein complex termed Cascade (CRISPR-associated complex for antiviral defence) 13 . The type I-E Cascade of Escherichia coli is well characterized and consists of (1) a crRNA, (2) the crRNA endonuclease Cas6, (3) Cas5, binding the 5′ end of the crRNA, (4) six Cas7 subunits, which form the helical backbone of Cascade via spacer binding, (5) Cse1 (large subunit), responsible for PAM recognition and (6) two copies of Cse2 (small subunit), which stabilize the non-target DNA strand 13, 14, 24 . Additionally, a gene coding for a structure-specific helicase, DinG 25 , is often found in the neighbouring regions of CRISPR modules, but its functional role in CRISPR-Cas systems is unknown. A minimal Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum Articles Nature Microbiology type I-F variant Cascade architecture consisting of three Cas proteins has been described for Shewanella putrefaciens and highlighted that Cas5 (binding the 5′ -repeat tag) and Cas6 (cleaving and binding the 3′ repeat) proteins cap a Cas7-crRNA backbone of variable length 26, 27 . The available knowledge on five of the six CRISPR-Cas types exists in stark contrast to the lack of experimental data on type IV systems. Computational analyses using a library of position-specific scoring matrices propose that type IV systems possess genes coding for potential paralogues of Cas5 (Csf3), Cas7 (Csf2) and a large subunit (Csf1) that acts as the signature protein for this type 19 . However, it is not clear if crRNAs are bound by these proteins and if functional RNPs are formed. Type IV CRISPR-Cas systems are usually localized on plasmids and lack apparent adaptation modules (cas1 and cas2) and genes for target cleavage enzymes (cas3 or cas10) 19 . This arrangement suggests that the unknown activity of type IV CRISPR-Cas systems might not rely on spacer acquisition or degradation of target DNA or, alternatively, that it relies on Cas proteins of unrelated systems. Here, we provide the first experimental analysis of the type IV CRISPR-Cas system of Aromatoleum aromaticum EbN1 to obtain insights into the functional roles of the associated Cas proteins. We show that a Cas6-like enzyme is required for specific crRNA maturation and subsequent crRNP formation, which demonstrates that type IV CRISPR-Cas systems employ crRNAguided effector complexes.
Results
Gene organization and crRNA maturation of A. aromaticum CRISPR-Cas systems. A model type IV CRISPR-Cas system was identified in A. aromaticum EbN1, a beta-proteobacterium with biotechnological use in the anaerobic degradation of recalcitrant organic pollutants. A. aromaticum contains a type I-C CRISPR-Cas system on its genome and a type IV CRISPR-Cas system on one of its two megaplasmids (Fig. 1) . A gene coding for a DinG helicase is located next to the type IV-associated CRISPR arrays. RNA sequencing (RNA-seq) of A. aromaticum RNA species revealed that the type I-C CRISPR system yields crRNAs with an 11 nt 5′ -terminal repeat tag (5′ -UGGAUUGAAAC-3′ ), which is in agreement with previous studies on type I-C systems 28 . These systems exhibit an unusual RNA processing pathway employing a variant of Cas5 for crRNA maturation 29, 30 . The CRISPR array contains 115 spacers and is divided into three fragments by the insertion of three transposon genes in antisense orientation. RNA-seq coverage suggests the formation of a long pre-crRNA with segments of antisense transposon RNA sequences. The corresponding transposon genes are found multiple times in the genome of A. aromaticum, and a physiological role of pre-crRNA/transposon mRNA interactions is possible. Mature crRNAs are found even for the very end of this CRISPR array (Fig. 1) . Next, we investigated the CRISPR array that is located near the type IV system of the A. aromaticum megaplasmid 1. The CRISPR array revealed low levels of transcription and mature crRNAs were sequenced (Fig. 1) . Surprisingly, these crRNAs harbour a 7 nt 5′ -terminal repeat tag (5′ -GUUGAAG-3′ ), which deviates from the standard 8 nt crRNA tag found in type I CRISPRCas systems. The structure of the repeats suggests that cleavage at the base of an extended hairpin with a 7 bp stem generates this shortened tag (Fig. 1b) . A conserved insertion sequence is located between two type IV CRISPR arrays and we propose that the insertion event occurred within a spacer element. Our RNA-seq studies also revealed few reads that match to the genomic locations of all cas genes. The low coverage suggests that the expression of the cas genes might require specific conditions or external signals for transcription activation.
Csf5 is responsible for type IV crRNA maturation. To allow for efficient Cas protein production and to study type IV crRNA maturation, all type IV cas genes (csf1, csf2, csf3 and csf5) of A. aromaticum were expressed in E. coli. In addition, a mini-CRISPR, consisting of a single repeat-spacer-repeat unit, was provided, and pre-crRNA production was monitored via northern blot using a probe against the spacer sequence. We observed that stable and mature crRNAs are only produced in E. coli when the mini-CRISPR and Csf5 are provided ( Fig. 2 and Supplementary Fig. 1 ) and conclude that Csf5 is a crRNA endonuclease of the Cas6 family, generating the unusual 7 nt 5-terminal repeat tag. Next, we aimed to investigate type IV CRISPR processing in vitro with recombinant proteins and pre-crRNA transcripts. Soluble Csf5 could only be produced in the presence of bound crRNA, and purification by affinity-and gel-filtration chromatography yielded milligram amounts of recombinant Csf5 proteins in complex with a crRNA component.
Structure of Csf5 in complex with a processed crRNA 3′-tag. The purified Csf5 preparations were subjected to structure determination by X-ray crystallography. Due to the lack of suitable search models for molecular replacement, we determined the structure of Csf5 by single anomalous dispersion (SAD) and subsequently solved the structure of the native variant at 1.75 Å resolution (Supplementary Table 1 ). The crystal structure revealed two monomers of the Csf5 protein associated with the crRNA 3′ -repeat tag within the asymmetric unit ( Fig. 3a and Supplementary Fig. 2 ). As anticipated from the pseudo-palindromic 3′ -tag sequence, nucleotides 6 to 22 fold into a stem-loop structure (hairpin) that is tightly enclosed by Csf5. Electron density for nucleotides 14 and 15 of the crRNA hairpin was missing in the electron density map, arguing for a degraded hairpin loop ( Supplementary Fig. 2a ). To investigate whether this degraded hairpin arose due to the activity of unspecific RNases during the purification at 20 °C, we subsequently purified Csf5 at 4 °C to reduce potential RNase activity. Crystallization and structure determination of the so-purified Csf5-crRNA complex revealed two monomers of Csf5 in complex with the intact crRNA stem-loop 3′ -repeat tag at a resolution of 2.3 Å (Supplementary Table 1 , Fig. 3b and Supplementary Figs. 2 and 3b) . With the exception of the degraded hairpin, both structures were highly similar in their configuration, as evidenced by superimposition and the low root-mean-square deviation (r.m.s.d.) values of < 0.3 Å between the structures (Supplementary Fig. 2c ). The structure revealed that Csf5 is not only a functional but also a structural homologue of the Cas6 superfamily. Csf5 features the typical two positively charged RNA recognition motifs (RRMs) of Cas6 proteins (that is, the N-terminal RRM and C-terminal RRM′ ), which largely mediate the RNA contacts and enclose the endonuclease active site that is located between both domains (Fig. 3) . Furthermore, Csf5 features a glycine-rich loop (G-loop) conserved within the Cas6 family that extrudes from RRM′ towards the active site. The G-loop was previously suggested to assist in the binding and stabilization of the crRNA (reviewed in ref. 31 ). Moreover, a characteristic β 2 ′ and β 3 ′ hairpin structure (β -HP) that assists in positioning the scissile phosphate, and the groove-binding element (GBE), which recognizes the major groove of the crRNA hairpin, could be identified. Other than those widely conserved Cas6 features, Csf5 also features an α -helical finger domain that connects β 1 and β 2 of the N-terminal RRM and interacts with the crRNA hairpin via the crRNA repeat hairpin minor groove, which probably contributes to the specificity and stability of crRNA binding. Comparison of Csf5 with known Cas6 structures revealed shared domain arrangements and unique structural features (Supplementary Table 2 and Supplementary Fig. 4 ).
Within the active site, we identified a 2′ , 3′ cyclic phosphate as the reaction product of the endonucleolytic crRNA repeat cleavage ( Fig. 3d and Supplementary Fig. 3c,d) . Hence, the nucleophilic attack of the scissile phosphate seems to be facilitated via the 2′ hydroxyl group of the 5′ upstream nucleotide (G22), as also observed for other Cas6 endonucleases (reviewed in ref. 31 ). 
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The active site is mainly shaped by three arginine residues (R23, R38 and R242) that surround the 2′ , 3′ cyclic phosphate and might participate in (1) activation of the 2′ hydroxyl group, (2) protonation of the leaving group and (3) stabilization of the transition state (Fig. 3d) . In agreement, mutations of individual arginine residues of Csf5 to alanine reduced levels of mature crRNAs in our recombinant E. coli system and increased levels of pre-crRNA transcripts ( Fig. 2 and Supplementary  Fig. 1b,c) . Among the three single mutants, R23A had the strongest effect, and double mutants of R23A with either of the other Arg residues resulted in a complete loss of pre-crRNA processing.
Serines 209 and 241 of the β -HP and the G-loop, respectively, might contribute to the positioning of the scissile phosphate and binding of the crRNA repeat at the active site. We further identified tartrate originating from the crystallization solution, bound in close proximity to G22 and histidine 44 ( Fig. 3d and Supplementary Fig. 3c,d) . Hence, the tartrate ligand might affect the position of histidine 44. However, Csf5 with an H44A mutation still produces mature crRNA in vivo, which excludes that a catalytic histidine is required for Csf5 activity (Supplementary Fig. 1c) . 
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Formation of a type IV crRNP complex. Production and maturation of a type IV-associated crRNA suggests that this RNA component is bound by other type IV Cas proteins to enable RNA-guided target detection. To follow the fate of the crRNA, the four Cas proteins Csf1, Csf2, Csf3 and Csf5 were simultaneously produced in E. coli and potential complexes were co-purified via a His-tag fused to Csf5. Large complexes in the void volume and a distinct crRNP were obtained after gel-filtration chromatography. The individual production of Csf2 also yielded large complexes, and RNA of high molecular weight was co-purified (Fig. 4) . Transmission electron microscopy (TEM) revealed that the large Csf2 complexes consist of helical filaments. Similar helical filaments that wrap around RNA molecules have previously been observed for Cas7 proteins in type I systems 26, 32 . These proteins exhibit unspecific binding to the crRNA spacer regions and form the backbone of Cascade. We conclude that Csf2 is a Cas7-family protein. Further analysis of type IV crRNP complexes revealed the presence of very similar amounts of Csf3 (Cas5-like), Csf5 (Cas6-like) and Csf1 (large subunit), whereas an increased abundance of Csf2 (Cas7-like) was observed. The presence of all four proteins was verified via mass spectrometry. It should be noted that this Cas7 variant (383 aa) is the largest of all four Cas proteins, and the postulated 'large' subunit 19 consists of only 261 aa and has a size similar to the Cas5-like (240 aa) and Cas6-like subunits (260 aa). Our results indicate that the type IV Cas7-like variant is represented by several subunits in a type IV crRNP, which is in agreement with its proposed role as a backbone protein that mediates crRNA spacer binding. TEM indicated that the crRNP complexes are small crescent-shaped molecules with dimensions that resemble the size of Cascade complexes (Fig. 4) . We attempted to produce the type IV crRNP with a crRNA of the A. aromaticum type I-C CRISPR. It was observed that Csf5 and crRNP stability relies on the presence of the type IV crRNAs, and type I-C pre-crRNA was not processed by Csf5 ( Supplementary  Fig. 1a) . Therefore, type IV CRISPR-Cas activity is proposed to rely on Cascade-like complexes and guidance by a specific type IV-associated crRNA component.
Protein-protein and protein-RNA interaction sites in type IV crRNPs. To obtain more insights into the type IV crRNP complex formed by Csf1, Csf2, Csf3, Csf5 and crRNA, we used protein-protein crosslinking and protein-RNA crosslinking approaches followed by mass spectrometry to identify corresponding interaction sites within the proteins. Protein-protein interactions were identified after applying chemical crosslinking with bis(sulfosuccinimidyl) suberate (BS3), which creates covalent bonds between lysine residues within the same or adjacent proteins located in close proximity to each other. We observed a multitude of homomultimeric links in Csf2, which strongly suggests that it is represented by more than one copy in type IV surveillance complexes. Csf2 also forms multiple crosslinks with all other proteins, which further strengthens the notion that Csf2 acts as a backbone in the complex. Importantly, no inter-crosslinks between Csf1 and Csf3 were detected, which indicates that these proteins are not in proximity to each other ( Fig. 5 and Supplementary Table 3 ). In turn, crosslinks between Csf1 and Csf5 suggest that these two subunits are probably located near the 3′ -end of the crRNA. To further verify the formation of a Cascade-like type IV crRNP complex, we identified interaction sites between crRNA and Cas protein components. Many amino acid residues of Csf2, Csf3 and Csf5 were found to be crosslinked with the crRNA (Supplementary Table 4) , most of them in Csf2, which supports the interactions between the crRNA spacer sequence and the crRNP backbone and within the crRNA endonuclease Csf5. Of the crosslinked residues of the latter, the crystal structure indicates that amino acid K157 interacts with U2 of the repeat sequence. Additional crosslinking sites of Csf5, S134, K142, Y144 and K157 are located within the RRM′ and RRM motifs and are suggested to be involved in guiding the spacer at the site of Csf2 and Csf5 interaction ( Supplementary Fig. 5 ).
Discussion
Type IV systems represent one of six computationally classified CRISPR-Cas systems 19, 20 and are the only ones without experimental data on Cas protein interactions, RNA components and functionality. 
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Type IV systems do not usually encode Cas1 and Cas2 proteins, and CRISPR arrays are often absent. The signature protein of these systems is the protein Csf1, which has been proposed to resemble the large subunit of type I systems. In this study we identified a model type IV system that contains all three commonly observed proteins Csf1, Csf2 and Csf3. In addition, a Cas6-like protein (Csf5) and an adjacent CRISPR array suggested that crRNA maturation is required for type IV systems. We verified that Csf5 acts as a Cas6-family enzyme, generating mature crRNAs. Crystal structures of RNA-bound Csf5 identified a conserved core fold and revealed that repeat RNA cleavage occurs at the base of a hairpin structure. This cleavage mode has been observed for other single-turnover Cas6 enzymes, in which the processed RNA remains bound and is delivered to effector complexes. A search for conserved residues near the catalytic site of Csf5 did not yield clear hits and the entire protein sequence exhibits at most 25% identity to other Cas6 enzymes. Most described Cas6 enzymes utilize a critical histidine for RNA cleavage 31 . This residue is absent in Csf5, and the mutation of a more distant histidine did not abolish activity, supporting the absence of a canonical catalytic histidine. A similar observation was made for a Cas6 enzyme of Sulfolobus solfataricus and it was argued that repeat RNA recognition and a chaperone-like activity is more relevant for some members of the Cas6 family than their enzymatic ribonuclease activity 33 . This scenario is also exemplified by the type I-C system in A. aromatoleum, in which an entirely different Cas protein, Cas5d, evolved a catalytic crRNA cleavage site. It is plausible that the absence of a genomically encoded Cas6 prevents possible crosstalk between type I-C and type IV crRNA processing pathways. Plasmid-encoded type IV systems that lack Csf5 might utilize Cas6 enzymes from different CRISPR-Cas systems to ensure that a necessary crRNA component is provided. In A. aromatoleum, Csf5 generates unusual 7 nt 5′ -repeat tags and relies on several arginine residues for efficient type IV-specific crRNA maturation.
Subsequently, these crRNAs are incorporated into crRNP complexes that contain Csf1, Csf3, Csf5 and multiple copies of Csf2. We observed that Csf2 forms a helical filament around RNA molecules, which resembles Cas7 functionality, and a combination of electron microscopy and mass spectrometry analyses highlighted similarities to other class 1 crRNP assemblies. A crescent-shaped complex is formed around the crRNA spacer, resembling Cascade size and overall structure. Consequently, this type IV CRISPR-Cas system yields crRNPs that would be able to scan target nucleic acids for complementarity. Two big questions arise from this scenario: (1) what (cr)RNA sequence information is needed for guidance in these complexes and (2) what happens if a target is recognized? Analysis of the type IV-associated spacers did not yield any matches including the host genome or viral genomes; only a few closely related bacteria and no specific phages are known for the genus Aromatoleum. An earlier computational analysis of 1,582 type IV-associated crRNAs revealed 147 spacers with hits 34 . Of these, 72% occurred within viral sequences, 3% in intergenic regions and 24% in open reading frames of potential hosts. The abundance of viral hits is similar to that for other CRISPR-Cas systems that function as adaptive immune systems against the targeted viruses. Therefore, it is possible that type IV CRISPR-Cas systems have a similar function or that they became associated with existing CRISPRs. The absence of type IV-associated CRISPRs would require crosstalk with genome-encoded CRISPRs to obtain a (structural) RNA component. However, some degree of specificity is needed, as we did not observe type IV crRNP formation with type I-C crRNAs. The function of type IV crRNPs remains to be elucidated. If adaptation and target cleavage enzymes were generally absent in a type IV system, a Cascade-like crRNP would continuously scan and restructure the host's genome and megaplasmids. It is possible that this process benefits the acquisition of mobile genetic elements that exploit DNA bending. In this respect, A. aromatoleum is noteworthy for its enormous number of mobile genetic elements, including over 200 transposase genes, which suggests that this organism might benefit from high genome plasticity and frequent lateral gene transfer.
Methods
A. aromaticum EbN1 growth conditions. A. aromaticum strain EbN1 was grown anaerobically in a 30 l fed-batch fermenter culture on minimal medium with benzoate Articles Nature Microbiology (3 mM) as sole carbon source and nitrate (10 mM) as electron acceptor 35 . Cells were harvested in exponential growth phase at optical densities (OD 578 nm) of 3.5-4.
Cloning of expression constructs. Type IV CRISPR-Cas loci cas genes were codon optimized and synthesized by Genescript and cloned into the two multiple cloning sites of pCDFDuet-1 (csf1 and csf5, pCsf1-Csf5) and pRSFDuet-1 (csf2 and csf3, pCsf2-Csf3) vectors (Novagen). In addition, csf5 and csf1 were cloned individually into pCDFDuet-1 to yield pCsf5 and pCsf1 plasmids and csf2 and csf3 were cloned individually into pRSFDuet-1 to yield pCsf2 and pCsf3 plasmids. A hexa-histidine tag was included at the 5′ end of csf5 for Ni-NTA (Ni-nitrilotriacetic acid) affinity chromatography of recombinant complexes. The repeat-spacer 1-repeat sequence was placed under control of a T7 RNA polymerase promoter cloned into the pUC19 vector (NEB) BamHI and HindIII restriction sites using two with annealed oligonucleotides (pminiCRISPR, Supplementary Table 5 ). QuikChange sitedirected mutagenesis (Agilent) was applied to obtain plasmids for the expression of Csf5 mutants. Wild-type and Csf5 mutant plasmids were verified by sequencing.
Production and purification of recombinant proteins. E. coli BL21-AI (Invitrogen) was transformed with the indicated expression plasmids (pCsf2-Csf3, pCsf1-Csf5 and pminiCRISPR were used to obtain the crRNP, pCsf5 and pminiCRISPR were used to purify RNA-bound Csf5). The expression cultures were grown at 37 °C in 1 l Lysogeny Broth (LB) medium with appropriate antibiotics (50 μ g ml −1 kanamycin and spectinomycin and 100 μ g ml −1 ampicillin) under rigorous shaking (200 r.p.m., B.Braun Biotech Certomat S) to an optical density at 600 nm (OD 600 ) of 0.6-0.8. Expression was induced with 1 mM isopropyl β -d-1-thiogalactopyranoside and 20% l-arabinose for 3-4 h. Cells were subsequently harvested by centrifugation (6,000 g, 4 °C). Cell pellets were re-suspended in lysis buffer (20 mM HEPES pH 7.5, 300 mM NaCI and 10 mM imidazole). Cells were lysed by addition of lysozyme for 30 min on ice and subsequently sonified (8 × 30 s: Branson Sonifier 250). The cell lysate was clarified by centrifugation (38,359 g, 30 min, 4 °C) and the supernatant was applied to a 5 ml HisTrap HP column (GE Healthcare). The column was washed with 10 column volumes of washing buffer (20 mM HEPES pH 7.5, 300 mM NaCI, 20 mM imidazole) before elution of bound proteins by an imidazole gradient (20-500 mM). Eluates were concentrated to a final volume of 2 ml and injected on a HiLoad 16/600 Superdex 200 column (GE Healthcare) equilibrated in SEC buffer (20 mM HEPES pH 7.5, 300 mM NaCl) for size exclusion chromatography. Peak fractions were analysed by SDS-and urea-PAGE. Csf5-crRNA complexes were purified by the same protocol and size exclusion chromatography was either performed at room temperature or 4 °C, yielding two different substrates for crystallization.
Electron microscopy. Carbon-coated copper grids (400 mesh) were hydrophilized by glow discharging (PELCO easiGlow, Ted Pella). A 5 μ l volume of a 13.7 μ g ml −1 protein suspension was applied onto the hydrophilized grids and stained with 2% uranyl acetate after a short washing step with double-distilled H 2 O. Samples were analysed with a JEOL JEM-2100 transmission electron microscope using an acceleration voltage of 120 kV. A F214 FastScan CCD camera (TVIPS, Gauting) was used for image acquisition. For 2D class averaging, a sample with a concentration of 0.4 mg ml −1 was diluted in H 2 O bidest to a final concentration of 20 µ g ml −1 and prepared as described above. A total of 30 montages (2 × 2 to 6 × 6 stitched single 2k images) were taken at 200 kV and processed with cisTEM 36 . For particle picking the cisTEM ab initio algorithm was used before manual editing (that is adding/deleting particles from the data set). A total of ~5,400 particles were used for averaging 10 classes (20 cycles).
RNA sequencing. Total RNA isolated from A. aromaticum EbN1 (5 g of cell pellets) was purified using mirVana RNA extraction kit (Ambion) with an enrichment of small RNAs (< 250 nt), then 3 μ g of isolated small RNA from A. aromaticum EbN1 was phosphorylated with T4 polynucleotide kinase (T4 PNK) to allow for termini ligation. RNA was incubated at 37 °C for 6 h with 10 U of T4 PNK (Ambion) and 10 μ l 5× T4 PNK buffer (0.5 M Tris-HCI pH 6.5, 0.5 M MgAc, 25 mM β -mercaptoethanol) in a total volume of 50 μ l. ATP (1 mM) was added and the reaction mixture was incubated for 1 h at 37 °C to obtain mono-phosphorylated 5′ termini. Afterwards, RNA library constructions with adaptors were prepared with an Illumina TruSeq RNA Sample Prep Kit, and sequencing on an Illumina HiSeq2000 sequencer was performed at the Max Planck-Genome-Centre Cologne.
Northern blot analysis. Total RNA (2 μ g) was loaded onto an 8 M urea 10% denaturing polyacrylamide gel. A semidry electrophoretic transfer system was used to transfer RNA bands onto a positively charged membrane (Roti-Nylon plus, pore size 0.45 μ m) for 2 h at 20 V and crosslinked with ultraviolet crosslinker (120 s). After the transfer, the membrane was pre-hybridized for 30 min at 55 °C in ULTRAhyb-Oligo hybridization buffer and non-specific binding was blocked. The membrane was incubated with 30-50 ng μ l −1 of digoxigenin (DIG)-labelled probes in 8 ml of hybridization buffer overnight at 55 °C. DIG-bound antibodies were detected by an X-ray imager film processor (Agfa-CP1000).
Crystallization and vaporizing iodine labelling. Purified Csf5 bound to the recognized crRNA repeat was concentrated to an absorbance at 280 nm of 50 AU 37 ) were generated by combining 1 µ l protein solution, containing purified Csf5 preparations at 20 °C, with 1 µ l crystallization solution (0.16 M di-ammonium tartrate, 16% wt/ vol PEG3350, 200 mM NaCl). Elongated-block-shaped crystals appeared after 2-3 days and were subsequently transferred into crystallization solution containing 20% glycerol for cryoprotection. The crystals were then incubated for 1.5 h in the presence of a 0.5 µ l drop of KI/I 2 solution (0.67 M KI and 0.47 M I 2 ) for VIL according to ref. 37 . Crystals were subsequently flash frozen and stored in liquid nitrogen. Native crystals of the 20 °C preparations were generated by combining 1 µ l protein solution with 1 µ l crystallization solution (0.18 M di-ammonium tartrate, 18% wt/vol PEG3350, 3% glycerol). Crystals appeared after 2-3 days and were subsequently transferred into crystallization solution containing 20% glycerol for cryoprotection. Crystals were then flash frozen and stored in liquid nitrogen. Crystals of the 4 °C preparations were generated by combining 1 µ l protein solution with 1 µ l crystallization solution (0.2 M di-sodium tartrate, 20% wt/vol PEG3350). Block-shaped crystals appeared after 4 days and were subsequently transferred into crystallization solution containing 20% glycerol for cryoprotection. Crystals were then flash frozen and stored in liquid nitrogen.
Data collection and structure determination. Diffraction data were collected at beamlines ID23-1 and ID29 of the European Synchrotron Radiation Facility (ESRF) in Grenoble, France 38 . Data were processed with the XDS program package for data reduction 39 , and merging and scaling was performed using the AIMLESS program as implemented in the CCP4 package 40 . Crank2 was used for experimental phasing of the VIL iodine derivative (CCP4 package 40 ). Coot 41 , in combination with Refmac5 (CCP4 package 40 ) and phenix.refine (PHENIX package 42 ), was used for iterative model building and refinement. The crystal structures of the 4 °C preparations were subsequently solved by molecular replacement using the CCP4 implemented program Phaser 43 . Figures were prepared in Pymol (www.pymol.org).
Protein-protein and protein-RNA crosslinking. To identify amino acids that interact with the crRNAs, 100 µ g of RNA-bound type IV crRNPs was ultravioletirradiated at 254 nm for 10 min, while a second sample served as a non-irradiated control. The protein-RNA samples were loaded onto a pre-packed C18 column (Harvard Apparatus, Microspin C18 Column), mounted to a Dionex UltiMate 3000 UHPLC + focused system (Thermo Scientific) equipped with an analytical column (75 μ m × 300 mm, ReproSil-Pur 120 C18-AQ, 1.9 μ m, Dr. Maisch GmbH, packed in house). Peptides were separated by reverse-phase chromatography on a 58 min multi-step gradient (flow rate of 0.3-0.4 µ l min ) before entering the mass spectrometer (QExactive HF-X, Thermo Scientific). MS1 spectra were recorded in profile mode (resolution of 120k), and MS2 spectra were recorded in centroid mode (resolution of 30k); the isolation window was set to 1.6 m/z and the dynamic exclusion was set to 7 s. Raw data of RNA-protein heteroconjugates were analysed and manually validated with the OpenMS pipeline RNPxl, as previously described in ref. 44 . For protein--protein crosslinking, 10 µ g aliquots of the complex were incubated with either 0.05, 0.1, 0.25, 0.5 or 1 mM BS3 (Thermo Scientific). Each of the samples was incubated at room temperature for 30 min and subsequently quenched by a final concentration of 50 mM Tris. Proteins were then separated by PAGE using a 4-12% gradient gel (NuPAGE, Invitrogen). The upper quarters of the lanes containing the complex crosslinked with 0.5 mM and 1 mM BS3 were cut into four equally sized slices and proteins were in-gel digested. Briefly, proteins were reduced and alkylated by 10 mM dithiotreitol and 55 mM iodoacetamide, respectively, and finally digested with trypsin at 37 °C for 18 h. Extracted and dried peptides were dissolved in 2% acetonitrile (ACN)/0.05% trifluoroacetic acid (TFA) and subjected to liquid chromatography-mass spectrometry (LC-MS) using the above mentioned set-up with the following changes: an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scientific) was used with a dynamic exclusion of 10 s and technical duplicates were measured. Raw files were converted to .mgf format with ProteomeDiscoverer 1.4 (Thermo Scientifc) and analysed with the software pLink (v. 1.23, pFind group 45 ) for identification of crosslinked peptides. Here, default settings were applied with carbamidomethylation of cysteines as fixed and oxidation of methionines as variable modifications, and the false discovery rate was set to 0.01. Results were filtered by excluding crosslinks supported by only one spectrum and additionally by applying a score cutoff value of 3. Interaction networks were visualized by xiNET 46 .
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding author upon request. Crystallographic data and models have been deposited at the protein data bank (PDB) under accession codes 6H9H and 6H9I. Data analysis RNA-seq: Illumina reads were trimmed (quality score limit of 0.05) and mapped to the reference genome of A. aromatoleum using CLC Genomics Workbench 5.0 (CLC Bio, Aarhus, Denmark). The following mapping parameters were used: mismatch cost: 2, insertion cost: 3, deletion cost: 3, length fraction: 0.5, similarity: 0.8.
Structure analysis: Data were processed with the XDS program package for data reduction merging and scaling was performed using the AIMLESS program as implemented in the CCP4 package. Crank2 was used for experimental phasing of the VIL iodine derivative (CCP4 package). Coot in combination with Refmac5 (CCP4 package) and phenix.refine (PHENIX package) was used for iterative model building and refinement. The crystal structure of the 4 °C preparations was subsequently solved by molecular replacement using via the CCP4 implemented program Phaser. Figures were prepared in Pymol (www.pymol.org).
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Mass-spectrometry: Raw data of RNA-protein heteroconjugates were analysed and manually validated with the OpenMS pipeline RNPxl . For protein-protein crosslinks, Raw files were converted to mgf format with ProteomeDiscoverer 1.4 (Thermo Scientifc) and analysed with the software pLink (v. 1.23, pFind group) for identification of crosslinked peptides. Here, default settings were applied with carbamidomethylation of cysteines as fixed and oxidation of methionines as variable modification, FDR was set to 0.01. Results were filtered by excluding crosslinks supported by only one spectrum and additionally by applying a score cut-off value of 3. Interaction networks were visualised by xiNET.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
Availability of data and materials: Crystallographic data and models have been deposited at the protein data bank (PDB) under accessions 6H9H and 6H9I.
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample size is not relevant for this study. We report the crystal structure of the Csf5 enzyme and the electron micrsoscopy structures of Csf2 and crRNP complexes.
Data exclusions No data was excluded from the analyses.
Replication
In vivo Csf5 cleavage assays and the production and TEM visualization of recombinant crRNPs and Csf2 filaments were repeated three times with similar results. The cross-linking experiments were conducted once for each cross-linker concentration and technical duplicates of every sample were measured on the mass spectrometer. RNA-seq analysis of crRNA termini are from a single experiment. For each crystal structure, the data was derived from a single crystal.
Randomization Randomization was not relevant for this study. Samples were not allocated into experimental groups.
Blinding
Blinding was not relevant for this study and group allocation during data collection was not performed.
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